Financials data is unavailable for this security.
View more
Year on year Cytek Biosciences Inc 's net income fell from a gain of 2.58m to a loss of 12.15m despite revenues that grew 17.67% from 164.04m to 193.02m. An increase in the selling, general and administrative costs as a percentage of sales from 41.41% to 48.24% was a component in the falling net income despite rising revenues.
Gross margin | 54.97% |
---|---|
Net profit margin | -8.88% |
Operating margin | -13.06% |
Return on assets | -3.48% |
---|---|
Return on equity | -4.32% |
Return on investment | -3.89% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Cytek Biosciences Inc fell by 131.87m. However, the company earned 5.28m from its operations for a Cash Flow Margin of 2.74%. In addition the company used 93.89m on investing activities and also paid 41.81m in financing cash flows.
Cash flow per share | -0.0793 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 2.96 |
---|---|
Tangible book value per share | 2.67 |
More ▼
Balance sheet in USDView more
Current ratio | 7.33 |
---|---|
Quick ratio | 6.38 |
Total debt/total equity | 0.0084 |
---|---|
Total debt/total capital | 0.0083 |
More ▼